Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete remission rate
30 days after end of immuno-chemotherapy
Gerald Illerhaus, PD Dr.
University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology
Germany: Federal Institute for Drugs and Medical Devices